ELISA - 世界市場の考察、競合情勢、市場予測（2030年）

世界のELISAの市場規模は、2023年に53億4,000万米ドル、2030年までに75億8,000万米ドルに達し、2024年～2030年の予測期間にCAGRで6.07％の成長が見込まれます。市場は、HIV、結核、マラリア、B型肝炎などの感染症の流行、ELISAの薬物乱用検査への応用の拡大、エンドユーザーにとってのELISAの精度、携帯性、入手性、使いやすさの向上への注目の高まりなどの要因によって活況を示す見込みであり、予測期間（2024年～2030年）に大きな収益成長が見込まれています。

ELISAの市場力学

ELISA市場の注目すべき促進要因の1つは、世界の性感染症患者の増加です。例えば、世界保健機関（WHO）（2022）によると、世界では毎日約100万人が性病に感染しています。また、同資料によると、2020年にクラミジアが約1億2,900万件、梅毒が710万件、淋病が8,200万件、トリコモナスが約1億5,600万件記録されると推定されています。

世界中で数百万人が罹患しているさまざまな種類のがんも、ELISA市場の促進要因の1つです。例えば、世界保健機関（WHO）（2022）の発表によると、2020年に約226万件の乳がん症例、221万件の肺がん症例、193万件の大腸がん症例が記録されています。また、成人人口の間で肺がん、乳がん、前立腺がんといったがんに対する意識が高まっていることや、医師がこれらの疾患のバイオマーカー検査を毎年推奨していることも、ELISA市場を加速させます。

ELISAは薬物乱用検査への応用が拡大しており、その需要が増加し、ELISA市場の成長にプラスの影響を与える可能性が高いです。例えば、United Nations Office on Drugs and Crime（UNODC）（2022）によると、昨年は世界で約2億7,500万人が薬物を使用し、3,600万人以上が薬物使用障害に苦しんでいます。テトラヒドロカンナビノール（THC）、メタドン、オピオイド、ベンゾジアゼピンなどを含む多くの薬物が乱用されており、ELISAは毛髪、血液、尿、口腔液、血清、血漿などのさまざまな生物学的検体中のこれらの薬物の存在を検出することができます。

また、製薬産業やバイオテクノロジー産業における継続的な研究開発が、再びELISA市場の成長につながっています。

しかし、代替製品の利用可能性やELISAに関連する制限が、ELISA市場の成長抑制要因として作用する可能性があります。

COVID-19期間中、ELISA市場は診断ツールや技術へのニーズの高まりにつながる患者数の増加により、わずかな成長を示しました。COVID-19パンデミックにより、FDAはELISAベースの診断キットを緊急用として大量に承認し、これがSars COV-2の検出に向けた高感度で信頼性の高いELISAベースの診断キットの開発につながっています。このため、ELISA市場にプラスの影響を与えています。パンデミックのシナリオは、2024年～2030年の予測期間のELISA市場に好影響を与えています。

ELISA市場のセグメント分析

ELISA市場の製品タイプセグメントでは、キット・試薬セグメントが大きな市場成長を記録する見込みです。

ELISAキット・試薬は、細菌、ウイルス、その他の抗原に対する抗体の迅速な検出と定量に広く利用されています。サイトカイン、成長因子、感染症や糖尿病や腫瘍のマーカー、薬物、低分子を含む何百種類ものタンパク質や分子は、ELISAキット・試薬によって検出することができます。

これらは、培養物やサンプル中の目的のターゲットを検出し定量するための、効果的かつ迅速で、便利で正確な研究ツールです。

そのため、この製品タイプに対する需要の高まりを考慮し、数多くの新製品が市場に投入されています。2022年9月、J Mitraは第4世代のElisaベースのHCV検査キット、HCV Gen 4 Ag & Ab Microlisaの発売を発表しました。このキットは、特に献血のスクリーニング、感染した血液の特定と排除、C型肝炎の臨床診断検査を目的としています。

当レポートでは、世界のELISA市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 ELISA市場レポートのイントロダクション

第2章 ELISA市場のエグゼクティブサマリー

• 調査範囲
• 市場の概要
• 競合の評価
• 財務ベンチマーク

第3章 規制分析

• 米国
• 欧州
• 日本
• 中国

第4章 ELISA市場の主な要因の分析

• ELISA市場の促進要因
  • 感染症の流行
  • 薬物乱用検査におけるELISAの需要の高まり
  • 腫瘍におけるELISAの応用の拡大
• ELISA市場の抑制要因と課題
  • 代替製品の利用可能性
  • ELISAに関連する制限
• ELISA市場の機会
  • 医療支出の増加
  • コスト効率の高い診断ツールに対する需要の増加

第5章 ELISA市場のポーターのファイブフォース分析

第6章 ELISA市場に対するCOVID-19の影響分析

第7章 ELISA市場のレイアウト

• 製品タイプ別
  • キット・試薬
  • ELISAシステム
  • その他
• 用途別
  • HIV
  • 妊娠検査
  • COVID-19
• エンドユーザー別
  • 病院、診断検査室
  • 製薬・バイオテクノロジー産業
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 ELISA市場：世界の企業シェア分析 - 主要3～5社

第9章 ELISA市場の企業と製品のプロファイル

• Abbott
• Erba Mannheim
• Synbiotik
• F. Hoffmann-La Roche Ltd
• Maccura Biotechnology Co.
• DiaSorin
• Thermo Fisher Scientific
• PerkinElmer Inc.
• Diatron
• Trivitron Healthcare
• Werfen
• BD
• ALPCO
• Quidel Corporation
• Agilent
• InBios International, Inc
• Awareness Technology, Inc.
• Elabscience Biotechnology Inc
• J. Mitra & Co. Pvt. Ltd.
• Rayto Life and Analytical Sciences Co., Ltd.

第10章 KOLの見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

List of Tables

• Table 1 Competitive Analysis
• Table 2 COVID-19 Impact Analysis on ELISA Market
• Table 3 ELISA Market in Global (2021-2030)
• Table 4 ELISA Market in Global by Product Type (2021-2030)
• Table 5 ELISA Market in Global by Application (2021-2030)
• Table 6 ELISA Market in Global by End-user (2021-2030)
• Table 7 ELISA Market in Global by Geography (2021-2030)
• Table 8 ELISA Market in North America (2021-2030)
• Table 9 ELISA Market in North America by Country (2021-2030)
• Table 10 ELISA Market in the US (2021-2030)
• Table 11 ELISA Market in Canada (2021-2030)
• Table 12 ELISA Market in Mexico (2021-2030)
• Table 13 ELISA Market in Europe (2021-2030)
• Table 14 ELISA Market in Europe by Country (2021-2030)
• Table 15 ELISA Market in France (2021-2030)
• Table 16 ELISA Market in Germany (2021-2030)
• Table 17 ELISA Market in the United Kingdom (2021-2030)
• Table 18 ELISA Market in Italy (2021-2030)
• Table 19 ELISA Market in Spain (2021-2030)
• Table 20 ELISA Market in Rest of Europe (2021-2030)
• Table 21 ELISA Market in APAC (2021-2030)
• Table 22 ELISA Market in APAC by Country (2021-2030)
• Table 23 ELISA Market in China (2021-2030)
• Table 24 ELISA Market in Japan (2021-2030)
• Table 25 ELISA Market in India (2021-2030)
• Table 26 ELISA Market in Australia (2021-2030)
• Table 27 ELISA Market in South Korea (2021-2030)
• Table 28 ELISA Market in Rest of APAC (2021-2030)
• Table 29 ELISA Market in Rest of World (2021-2030)
• Table 30 ELISA Market in RoW by Region (2021-2030)
• Table 31 ELISA Market in Middle East (2021-2030)
• Table 32 ELISA Market in Africa (2021-2030)
• Table 33 ELISA Market in South America (2021-2030)

List of Figures

• Figure 1 Competitive Analysis
• Figure 2 COVID-19 Impact Analysis on ELISA Market
• Figure 3 ELISA Market in Global (2021-2030)
• Figure 4 ELISA Market in Global by Product Type (2021-2030)
• Figure 5 ELISA Market in Global by Application (2021-2030)
• Figure 6 ELISA Market in Global by End-user (2021-2030)
• Figure 7 ELISA Market in Global by Geography (2021-2030)
• Figure 8 ELISA Market in North America (2021-2030)
• Figure 9 ELISA Market in North America by Country (2021-2030)
• Figure 10 ELISA Market in the US (2021-2030)
• Figure 11 ELISA Market in Canada (2021-2030)
• Figure 12 ELISA Market in Mexico (2021-2030)
• Figure 13 ELISA Market in Europe (2021-2030)
• Figure 14 ELISA Market in Europe by Country (2021-2030)
• Figure 15 ELISA Market in France (2021-2030)
• Figure 16 ELISA Market in Germany (2021-2030)
• Figure 17 ELISA Market in the United Kingdom (2021-2030)
• Figure 18 ELISA Market in Italy (2021-2030)
• Figure 19 ELISA Market in Spain (2021-2030)
• Figure 20 ELISA Market in Rest of Europe (2021-2030)
• Figure 21 ELISA Market in APAC (2021-2030)
• Figure 22 ELISA Market in APAC by Country (2021-2030)
• Figure 23 ELISA Market in China (2021-2030)
• Figure 24 ELISA Market in Japan (2021-2030)
• Figure 25 ELISA Market in India (2021-2030)
• Figure 26 ELISA Market in Australia (2021-2030)
• Figure 27 ELISA Market in South Korea (2021-2030)
• Figure 28 ELISA Market in Rest of APAC (2021-2030)
• Figure 29 ELISA Market in Rest of World (2021-2030)
• Figure 30 ELISA Market in RoW by Region (2021-2030)
• Figure 31 ELISA Market in Middle East (2021-2030)
• Figure 32 ELISA Market in Africa (2021-2030)
• Figure 33 ELISA Market in South America (2021-2030)
• Figure 34 Market Drivers
• Figure 35 Market Barriers
• Figure 36 Marker Opportunities
• Figure 37 PORTER'S Five Force Analysis

ELISA MARKET BY PRODUCT TYPE (KITS AND REAGENTS, ELISA SYSTEMS, AND OTHERS), BY APPLICATION (HIV, PREGNANCY TESTING, COVID-19, AND OTHERS), BY END-USER (HOSPITALS AND DIAGNOSTIC LABS, PHARMACEUTICAL AND BIOTECH INDUSTRIES, AND OTHERS), BY GEOGRAPHY IS ESTIMATED TO REGISTER GROWTH AT A REMARKABLE CAGR FORECAST DURING 2024-2030 OWING TO SURGE IN PREVALENCE OF INFECTIOUS DISEASES AND CONTINUOUS RESEARCH AND DEVELOPMENT ACTIVITIES HAPPENING IN PHARMACEUTICAL AND BIOTECH INDUSTRIES.

The global ELISA market was valued at USD 5.34 billion in 2023, growing at a CAGR of 6.07% during the forecast period from 2024 to 2030 to reach USD 7.58 billion by 2030. The ELISA market is slated to witness prosperity owing to factors such as growing prevalence of infectious diseases such as HIV, tuberculosis, malaria, and hepatitis B among others, growing application of ELISA for drug abuse testing, and the growing focus on improving the accuracy, portability, affordability, and usability of ELISA for end users are further expected to result in the appreciable revenue growth in the ELISA Market during the forecast period (2024-2030).

ELISA MARKET DYNAMICS:

One of the noteworthy drivers of the ELISA market is the elevation in cases of sexually transmitted diseases worldwide. For instance, according to World Health Organization (WHO) 2022, worldwide around 1 million people acquire STDs every day. Also, as per the same source, it was estimated that there were around 129 million cases of chlamydia, 7.1 million cases of syphilis, 82 million cases of gonorrhea, and around 156 million cases of trichomoniasis recorded in 2020.

The different cancer types affecting millions of people worldwide is another driver for ELISA market. For instance as per the World Health Organization (WHO) 2022, there were around 2.26 million cases of breast cancer, 2.21 million cases of lung cancer 1.93 million cases of colon and rectal cancer, recorded in 2020. Also, the rising awareness on cancer such as lung, breast, and prostate cancer amongst the adult population as well as recommendation of annual tests of biomarkers of these diseases by doctors is going to accelerate the market of ELISA.

The rising application of ELISA in drug abuse testing is likely to increase its demand, thus positively impacting the market growth for ELISA market. For instance, according United Nations Office on Drugs and Crime (UNODC) 2022, around 275 million people used drugs worldwide in the last year, while over 36 million people suffered from drug use disorders. The number of drugs including Tetrahydrocannabinol (THC), methadone, opioids, benzodiazepines, and others are abused by many and ELISA is capable of detecting the presence of these drugs in various biological specimens such as hair, blood, urine, oral fluid, serum, plasma, and others.

Also, the continuous research and development across pharmaceutical and biotechnology industries is again leading towards the growth in ELISA market.

However, the availability of alternative products and limitations associated with ELISA may act as restraining factors to the ELISA market growth.

During the period of COVID-19 infection, the ELISA market witnessed slight growth owing to increased number of cases of leading to increased need of diagnostic tools and technologies. The COVID-19 pandemic resulted in vast FDA approvals of ELISA based diagnostic kits under emergency use status which further led to the development of sensitive and reliable ELISA based diagnostic kits for the detection of Sars COV-2. Thus, positively impacting the ELISA market. The pandemic scenario has been uplifting for the ELISA market during the forecast period from 2024-2030.

ELISA MARKET SEGMENT ANALYSIS:

ELISA Market by Product Type (Kits and Reagents, Elisa Systems, and Others), Application (HIV, Pregnancy Testing, COVID- 19, and Others), End-User (Hospitals, Biotechnology Industries, Pharmaceutical Industries and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Based on the product type segment of the ELISA market, the kits and reagents segment is going to register a significant market growth.

ELISA kits and reagents are widely utilized for the rapid detection and quantification of antibodies against bacteria, viruses, as well as other material antigens. The hundreds of different proteins and molecules including cytokines, growth factors, markers for infectious diseases, diabetes and tumor, drugs and small molecules can be detected through ELISA kits and reagents.

These are effective, quick, convenient, and accurate research tool for the detection and quantitation of targets of interest in cultures and samples.

Therefore, considering the growing demand for this product type, numerous new products are being launched in the market. In September 2022, J Mitra announced the launch of their 4th Generation Elisa-based HCV Test-the HCV Gen 4 Ag & Ab Microlisa. The kit is particularly intended for screening blood donations to identify and eliminate the infected units of blood and for clinical diagnostic testing of Hepatitis C.

Therefore, considering the advantages and applications associated with ELISA kits and reagents and their growing popularity among end users, this product category is expected to generate considerable revenue thereby pushing the overall growth of the global ELISA market during the forecast period.

NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL ELISA MARKET:

Among all the regions, North America is expected to lead in revenue generation in the global ELISA market. This can be ascribed to the presence of large patient pool associated with infectious diseases, government support, high consumer awareness regarding new market launches and a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region.

The increasing prevalence of infectious diseases such as malaria, tuberculosis, hepatitis B, and other are likely to accelerate the growth of ELISA market. As per Centers for Diseases Control and Prevention 2022, around 7,860 new cases of tuberculosis were reported in the US in 2022. According to CDC 2022, each year nearly 2,000 cases of malaria are reported in the US.

Moreover, increasing number of blood donations and blood transfusions in the region necessitates the use of ELISA kits for the detection of hepatitis B and other infections in order to avoid the risk of transfusion of infected blood in patients. For instance, as per the Centers for Disease Control and Prevention 2020, there are around 13.2 million blood donors in the United States, resulting in a total of 17.2 million transfused blood product units per year.

One of the prominent factors supporting the growth of the North America ELISA market is the extensive use of ELISA in the detection of tumor markers indicating cancer development. As per American Cancer Society 2022, it has been estimated that around 1.9 million new cancer cases will be diagnosed in the US in 2022. Also, according to Centers for Disease Control and Prevention (CDC) 2022, around 1,752,735 new cancer cases were reported in 2019 in the US.

Therefore, the presence of large number of patients coupled with the increasing focus of manufacturers on launching new products in the market is expected to bolster the growth of the ELISA market in the United States during the forecast period.

ELISA MARKET KEY PLAYERS:

Some of the key market players operating in the ELISA market includes Abbott, F. Hoffmann-La Roche Ltd, Erba Mannheim, Synbiotik, Maccura Biotechnology Co., Ltd., Thermo Fisher Scientific, DiaSorin, PerkinElmer Inc., Diatron, Werfen, ALPCO, Agilent, InBios International Inc., Awareness Technology Inc., Elabscience Biotechnology Inc., J. Mitra & Co. Pvt. Ltd., Rayto Life and Analytical Sciences Co.,Ltd., BD, Trivitron Healthcare, and others.

RECENT DEVELOPMENTAL ACTIVITIES IN ELISA MARKET:

In February 2022, Agilent Technologies Inc. announced the launch of the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit for the qualitative detection of immunoglobulin G (IgG) antibodies to SARS-CoV-2 in human serum or plasma

In April 2020, ERBA Mannheim announced the launch of its CE ErbaLisa® COVID-19 ELISA kits

In November 2020, Enzo announced the launch of portable microplate reader for its elisa and other assay kits

KEY TAKEAWAYS FROM THE ELISA MARKET REPORT STUDY

• Market size analysis for current ELISA Market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the ELISA market.
• Top key product/services/technology developments, mergers, acquisitions, partnerships, joint ventures happened for last 3 years
• Key companies dominating the global ELISA market.
• Various opportunities available for the other competitor in the ELISA market space.
• What are the top performing segments in 2023? How these segments will perform in 2030.
• Which is the top-performing regions and countries in the current ELISA market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for ELISA market growth in the coming future?

TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS ELISA MARKET REPORT STUDY

• ELISA products providers
• Research organizations and consulting companies
• ELISA -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in ELISA
• Various end users who want to know more about the ELISA market and latest technological developments in the ELISA market.

FREQUENTLY ASKED QUESTIONS FOR ELISA MARKET:

1. What is ELISA?

ELISA is a type of plate-based diagnostic assay that is designed for detecting and quantifying soluble substances such as peptides, proteins, antibodies, and hormones based on specific reaction between antigen-antibody and thus helping in disease diagnosis.

2. What is the market for the global ELISA?

The global ELISA market was valued at USD 5.34 billion in 2023, growing at a CAGR of 6.07% during the forecast period from 2024 to 2030 to reach USD 7.58 billion by 2030.

3. What are the drivers for the global ELISA market?

The ELISA market is slated to witness prosperity owing to factors such as growing prevalence of infectious and other chronic diseases such as cancer, HIV, and others, increasing research and development activities across biotech and pharmaceutical industries, increasing healthcare expenditure, and the growing focus on improving the accuracy, affordability, portability, and usability of ELISA for end users are further expected to result in the appreciable revenue growth in the ELISA market during the forecast period (2024-2030).

4. Who are the key players operating in the global ELISA market?

Some of the key market players operating in the ELISA market includes Abbott, F. Hoffmann-La Roche Ltd, Erba Mannheim, Synbiotik, Maccura Biotechnology Co., Ltd., Thermo Fisher Scientific, DiaSorin, PerkinElmer Inc., Diatron, Werfen, ALPCO, Agilent, InBios International Inc., Awareness Technology Inc., Elabscience Biotechnology Inc., J. Mitra & Co. Pvt. Ltd., Rayto Life and Analytical Sciences Co.,Ltd., BD, Trivitron Healthcare, and others.

5. Which region has the highest share in the ELISA market?

North America is expected to dominate the overall ELISA Market during the forecast period, 2024 to 2030. This can be ascribed to the presence of large patient pool associated with infectious and other diseases, high consumer awareness regarding new market launches, government support, and a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region.

Table of Contents

1. ELISA Market Report Introduction

2. ELISA Market Executive Summary

• 2.1 Scope of the Study
• 2.2 Market at Glance
• 2.3 Competitive Assessment
• 2.4 Financial Benchmarking

3. Regulatory Analysis

• 3.1 The United States
• 3.2 Europe
• 3.3 Japan
• 3.4 China

4. ELISA Market Key Factors Analysis

• 4.1 ELISA Market Drivers
  • 4.1.1 Increasing prevalence of infectious diseases
  • 4.1.2 Rising demand of ELISA for drug abuse testing
  • 4.1.3 Expanding the applications of ELISA in oncology
• 4.2 ELISA Market Restraints and Challenges
  • 4.2.1 Availability of alternative products
  • 4.2.2 Limitations associated with ELISA
• 4.3 ELISA Market Opportunities
  • 4.3.1 Increasing healthcare expenditure
  • 4.3.2 Increasing demand for cost effective diagnostic tools

5. ELISA Market Porter's Five Forces Analysis

• 5.1 Bargaining Power of Suppliers
• 5.2 Bargaining Power of Consumers
• 5.3 Threat of New Entrants
• 5.4 Threat of Substitutes
• 5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on ELISA Market

7. ELISA Market Layout

• 7.1 By Product Type
  • 7.1.1 Kits and Reagents
  • 7.1.2 ELISA Systems
  • 7.1.3 Others
• 7.2 By Application
  • 7.2.1 HIV
  • 7.2.2 Pregnancy Testing
  • 7.2.3 COVID-19
  • 7.2.4 Others
• 7.3 By End-users
  • 7.3.1 Hospitals and Diagnostic Labs
  • 7.3.2 Pharmaceutical & Biotech Industries
  • 7.3.3 Others
• 7.4 By Geography
  • 7.4.1 North America
    • 7.4.1.1 United States ELISA Market in USD million (2021-2030)
    • 7.4.1.2 Canada ELISA Market in USD million (2021-2030)
    • 7.4.1.3 Mexico ELISA Market in USD million (2021-2030)
  • 7.4.2 Europe
    • 7.4.2.1 France ELISA Market in USD million (2021-2030)
    • 7.4.2.2 Germany ELISA Market in USD million (2021-2030)
    • 7.4.2.3 United Kingdom ELISA Market in USD million (2021-2030)
    • 7.4.2.4 Italy ELISA Market in USD million (2021-2030)
    • 7.4.2.5 Spain ELISA Market in USD million (2021-2030)
    • 7.4.2.6 Rest of Europe ELISA Market in USD million (2021-2030)
  • 7.4.3 Asia-Pacific
    • 7.4.3.1 China ELISA Market in USD million (2021-2030)
    • 7.4.3.2 Japan ELISA Market in USD million (2021-2030)
    • 7.4.3.3 India ELISA Market in USD million (2021-2030)
    • 7.4.3.4 Australia ELISA Market in USD million (2021-2030)
    • 7.4.3.5 South Korea ELISA Market in USD million (2021-2030)
    • 7.4.3.6 Rest of Asia Pacific ELISA Market in USD million (2021-2030)
  • 7.4.4 Rest of the World (RoW)
    • 7.4.4.1. Middle East ELISA Market in USD million (2021-2030)
    • 7.4.4.2 Africa ELISA Market in USD million (2021-2030)
    • 7.4.4.3 South America ELISA Market in USD million (2021-2030)

8. ELISA Market Global Company Share Analysis - Key 3-5 Companies

9. ELISA Market Company and Product Profiles

• 9.1 Abbott
  • 9.1.1. Company Overview
  • 9.1.2. Company Snapshot
  • 9.1.3. Financial Overview
  • 9.1.4. Product Listing
  • 9.1.5. Entropy
• 9.2 Erba Mannheim
  • 9.2.1. Company Overview
  • 9.2.2. Company Snapshot
  • 9.2.3. Financial Overview
  • 9.2.4. Product Listing
  • 9.2.5. Entropy
• 9.3 Synbiotik
  • 9.3.1. Company Overview
  • 9.3.2. Company Snapshot
  • 9.3.3. Financial Overview
  • 9.3.4. Product Listing
  • 9.3.5. Entropy
• 9.4 F. Hoffmann-La Roche Ltd
  • 9.4.1. Company Overview
  • 9.4.2. Company Snapshot
  • 9.4.3. Financial Overview
  • 9.4.4. Product Listing
  • 9.4.5. Entropy
• 9.5 Maccura Biotechnology Co.
  • 9.5.1. Company Overview
  • 9.5.2. Company Snapshot
  • 9.5.3. Financial Overview
  • 9.5.4. Product Listing
  • 9.5.5. Entropy
• 9.6 DiaSorin
  • 9.6.1. Company Overview
  • 9.6.2. Company Snapshot
  • 9.6.3. Financial Overview
  • 9.6.4. Product Listing
  • 9.6.5. Entropy
• 9.7 Thermo Fisher Scientific
  • 9.7.1. Company Overview
  • 9.7.2. Company Snapshot
  • 9.7.3. Financial Overview
  • 9.7.4. Product Listing
  • 9.7.5. Entropy
• 9.8 PerkinElmer Inc.
  • 9.8.1. Company Overview
  • 9.8.2. Company Snapshot
  • 9.8.3. Financial Overview
  • 9.8.4. Product Listing
  • 9.8.5. Entropy
• 9.9 Diatron
  • 9.9.1. Company Overview
  • 9.9.2. Company Snapshot
  • 9.9.3. Financial Overview
  • 9.9.4. Product Listing
  • 9.9.5. Entropy
• 9.10 Trivitron Healthcare
  • 9.10.1. Company Overview
  • 9.10.2. Company Snapshot
  • 9.10.3. Financial Overview
  • 9.10.4. Product Listing
  • 9.10.5. Entropy
• 9.11 Werfen
  • 9.11.1. Company Overview
  • 9.11.2. Company Snapshot
  • 9.11.3. Financial Overview
  • 9.11.4. Product Listing
  • 9.11.5. Entropy
• 9.12 BD
  • 9.12.1. Company Overview
  • 9.12.2. Company Snapshot
  • 9.12.3. Financial Overview
  • 9.12.4. Product Listing
  • 9.12.5. Entropy
• 9.13 ALPCO
  • 9.13.1. Company Overview
  • 9.13.2. Company Snapshot
  • 9.13.3. Financial Overview
  • 9.13.4. Product Listing
  • 9.13.5. Entropy
• 9.14 Quidel Corporation
  • 9.14.1. Company Overview
  • 9.14.2. Company Snapshot
  • 9.14.3. Financial Overview
  • 9.14.4. Product Listing
  • 9.14.5. Entropy
• 9.15 Agilent
  • 9.15.1. Company Overview
  • 9.15.2. Company Snapshot
  • 9.15.3. Financial Overview
  • 9.15.4. Product Listing
  • 9.15.5. Entropy
• 9.16 InBios International, Inc
  • 9.16.1. Company Overview
  • 9.16.2. Company Snapshot
  • 9.16.3. Financial Overview
  • 9.16.4. Product Listing
  • 9.16.5. Entropy
• 9.17 Awareness Technology, Inc.
  • 9.17.1. Company Overview
  • 9.17.2. Company Snapshot
  • 9.17.3. Financial Overview
  • 9.17.4. Product Listing
  • 9.17.5. Entropy
• 9.18 Elabscience Biotechnology Inc
  • 9.18.1. Company Overview
  • 9.18.2. Company Snapshot
  • 9.18.3. Financial Overview
  • 9.18.4. Product Listing
  • 9.18.5. Entropy
• 9.19 J. Mitra & Co. Pvt. Ltd.
  • 9.19.1. Company Overview
  • 9.19.2. Company Snapshot
  • 9.19.3. Financial Overview
  • 9.19.4. Product Listing
  • 9.19.5. Entropy
• 9.20 Rayto Life and Analytical Sciences Co.,Ltd.
  • 9.20.1. Company Overview
  • 9.20.2. Company Snapshot
  • 9.20.3. Financial Overview
  • 9.20.4. Product Listing
  • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us